PMCF — the bridge from real-world data to the CER

This blog post explains the role of Post-Market Clinical Follow-Up (PMCF) as an integral part of Clinical Evaluation (CER), the relevant regulatory requirements, how to plan and conduct PMCF effectively, and how PMCF results are systematically integrated into CER, risk management, and the Instructions for Use (IFU) and labeling. We also provide practical guidance on suitable data sources, how to evaluate signals, and the organizational prerequisites for successful and audit-proof PMCF projects.

Abbreviations

CEP	Clinical evaluation plan
CERIUM	Clinical Evaluation Report
MDR	Medical Device Regulation (EU Ordinance 2017/745)
Pmcf	Post-Market Clinical Follow-up
Pms	Post-Market Surveillance

Underlying regulations, standards and guidelines

EU Regulation 2017/745 (MDR)

MDCG 2020-7

MDCG 2020-8

1 Introduction

Post-Market Clinical Follow-Up (PMCF) is far more than simply collecting data retrospectively; it is a strategic, methodically driven tool that enables manufacturers to address specific open questions regarding the safety and clinical performance of a product. In light of the MDR (particularly Article 61, paragraph 11, and Annex XIV, Part B), PMCF is not optional but rather an integral part of the ongoing commitment to maintaining the Clinical Evaluation (CER) throughout the entire product lifecycle. PMCF provides the high-quality, prospectively collected clinical data necessary to support claims, substantiate benefit-risk analyses, and fill data gaps precisely where general post-market surveillance data (vigilance, symptoms) are insufficient.

PMCF should not be viewed in isolation, but rather as an integral, clinical component within the broader post-market surveillance (PMS) system. While PMS, as an "umbrella process," combines reactive (vigilance, complaints, FSCA) and proactive (user feedback) data, PMCF is the targeted, methodologically controlled activity that addresses the gaps left by non-clinical PMS data: PMCF provides the systematically collected clinical data to answer open questions and test specific hypotheses from the CER.

This close integration—PMS as a broad data collection tool and PMCF as a clinical review and closure function—creates a single evidence loop: Both provide directly usable inputs for clinical evaluation (CER), the risk management file (ISO 14971), and IFU/label adjustments. The result is a closed control loop: PMS detects signals, PMCF validates or refutes hypotheses with high methodological rigor, and the insights gained are fed back into benefit-risk analyses and claims assessments in the CER in an audit-proof manner. And all this with data from routine clinical practice…

2. Core requirements of the MDR

The MDR makes PMCF not an optional favor, but an integral, ongoing obligation: Article 61, paragraph 11, and Annex XIV, Part B, require that post-market clinical follow-up be methodically planned, continuously conducted, and its results systematically incorporated into the clinical evaluation (CER) and risk management. For manufacturers, this means specifically: PMCF is an ongoing process that confirms the safety and performance assumptions of a product throughout its expected lifespan, keeps residual risks verifiable, and identifies emerging risks.

Article 61 paragraph 11 of the MDR is a clear, practical mandate for manufacturers:

(11) The clinical evaluation and the accompanying documentation shall be updated throughout the product life cycle on the basis of the clinical data obtained from the implementation of the clinical follow-up plan in accordance with Part B of Annex XIV and the post-market surveillance plan in accordance with Article 84.

Annex XIV, Part B: Post-marketing clinical follow-up

5. Post-market clinical follow-up is understood as an ongoing process for updating the clinical evaluation in accordance with Article 61 and Part A of this Annex and is addressed in the manufacturer's post-market surveillance plan. In post-market clinical follow-up, the manufacturer proactively collects and evaluates clinical data arising from the use in or on the human body of a CE-marked product that has been placed on the market or put into service within the scope of its intended purpose in accordance with the relevant conformity assessment procedure, in order to confirm the safety and performance during the expected lifetime of the product, to ensure the continuing acceptability of the identified risks, and to identify emerging risks based on relevant evidence.

6. Post-marketing clinical follow-up will be according to a method set out in a post-marketing clinical follow-up plan.

…

7. The manufacturer analyzes the findings from post-market clinical follow-up and documents the results in a post-market clinical follow-up evaluation report; this report forms part of the clinical evaluation report and the technical documentation.

 8. The conclusions of the post-marketing clinical follow-up evaluation report are taken into account in the clinical evaluation pursuant to Article 61 and Part A of this Annex and in the risk management pursuant to Annex I, Section 3. If the post-marketing clinical follow-up identifies the need for preventive and/or corrective action, the manufacturer shall implement such action.

In practical terms, this means that questions for PMCF are derived directly from identified data gaps in the CER or from signals from the PMS, that a methodologically sound documented PMCF plan is available, and that the results are compiled in an evaluation report that is an integral part of the technical documentation.

Finally, the MDR requires that conclusions derived from PMCF results be incorporated into both the CER's benefit-risk analysis and the risk management file, and, if necessary, implemented in the form of preventive or corrective actions.

3. General and specific methods

PMCF employs a range of methods, selected and combined according to the research question, product characteristics, and feasibility. General methods include the structured collection of clinical experience from routine operations, such as hospital or outpatient data, as well as the systematic gathering of user feedback, surveys, and training results that provide insights into use-related risks. The evaluation of scientific literature complements this practical data and helps to place PMCF findings in an external context.

For targeted research questions, more specific designs are required. Product registries are particularly suitable for implants or widely used applications because they prospectively provide standardized outcome data over long periods. Prospective PMCF studies with a clear hypothesis, defined endpoints, and an a priori statistical design are the gold standard when it comes to methodically addressing a specific uncertainty in the CER. In addition, structured observational studies or retrospective analyses of medical records and registries are pragmatic options for quickly testing hypotheses or preparing the planning of prospective studies. Crucially, the choice of method depends on the research question: PMCF designs must be chosen to actually answer the questions formulated in the CER.

4. PMCF as a direct interface to clinical evaluation — how the integration works

PMCF is not an optional add-on; it is the lifeblood of your CER. In practical terms, this means that PMCF has a direct impact in two areas. First, PMCF specifically addresses the evidence gaps that remained during the marketing authorization process: endpoints, subgroups, or long-term questions not covered by preclinical studies are prospectively investigated and supported by robust rates and analyses. Second, PMCF provides real-world verification of your claims: the data show whether safety and performance are confirmed in everyday clinical practice or whether adjustments are necessary, be it to the benefit-risk matrix, claims in the IFU/label, or technical/organizational risk controls.

The integration process follows a transparent sequence: a PMCF trigger (CER gap or PMS signal) leads to the definition of a clear question and a PMCF plan with endpoint definitions. Data collection is carried out using the appropriate methodology (registries, prospective cohort, observational study). The results are formally summarized in the PMCF assessment report and incorporated into the PSUR/PMS report and the next CER version. Based on the data, the benefit-risk analysis is reviewed: claims are confirmed, refined, limited, or withdrawn; new risks are identified and recorded in the risk management file; necessary measures (IFU adjustment, CAPA, design changes, further PMCF) are implemented, and their effectiveness is subsequently monitored.

Without PMCF, the CER remains static and loses its connection to practice. With PMCF, however, you can demonstrate that your benefit-risk profile is up-to-date, your chain of evidence is traceable, and the clinical performance of your product has been proven in routine use. PMCF thus connects regulatory requirements with clinical reality: it fills gaps, validates claims, identifies new risks early on, and feeds the insights gained directly back into PMS, PSUR, and CER—in short, PMCF is the bridge between regulatory approval and everyday clinical practice.

5. Common mistakes (and how to avoid them)

PMCF is one of the most effective tools under the MDR, but also one of the most misunderstood. Even manufacturers who prepare well often stumble in its practical implementation and especially in its documentation. However, the typical pitfalls can be avoided by following clear principles.

A common mistake is treating PMCF as a one-off project: the study is conducted, the report filed, and the matter is considered closed. PMCF, however, is an ongoing process that extends throughout the entire product lifecycle. This problem can be avoided through regular reviews (at least annually for higher-risk products), the systematic integration of results into PMS, PSUR, and CER, and clear planning for follow-up analyses and potential expansions of the PMCF should new questions arise.

Equally critical is the lack of a link between PMCF and the Clinical Evaluation Report (CER). Results stored in isolation in a PMCF folder are of little use if they do not directly address the clinical claims or CER chapters. PMCF reports should already describe which CER update the data are incorporated into. This makes it clear which PMCF data supported or modified which conclusions in the CER.

Often, the methodological choice is justified too superficially: "We're conducting a survey" is not sufficient for notified bodies as a rational method for answering a specific open-ended question. Every PMCF method must justify why it is appropriate for the respective research question. This means explaining why registry data, a prospective cohort study, or an observational analysis addresses the remaining uncertainty, ideally with reference to the MDCG guidance on selecting appropriate methods.

Another mistake is collecting PMCF results but failing to translate them into action. If the data doesn't lead to entries in the Risk File, adjustments to the IFU, or CAPA measures, PMCF remains merely paperwork. Therefore, clearly document which PMCF findings triggered which specific decisions and demonstrate the subsequent effectiveness review. Auditors expect evidence that PMCF is not an end in itself, but actively guides risk management and clinical evaluation.

In short: PMCF is only as strong as its integration. If PMCF data is not systematically fed back into CER, PMS, and PSUR, it's not compliance, but rather formal fulfillment without clinical benefit. In practice, it's advisable to think of PMCF as your real-world clinical validation system: manage PMCF continuously, seamlessly link it to CER and Risk File, methodically justify every choice, and ensure high data quality and verifiable actions.

6. Conclusion

PMCF is the methodological core of post-market clinical evidence generation: well-planned and rigorously executed, it delivers the robust, real-world data that support claims, update benefit-risk analyses, and fill data gaps in the CER. PMCF is not an afterthought, but a strategic tool that enhances patient safety and ensures the regulatory robustness of your product, provided that PMCF activities are well-documented and fully integrated into CER and risk management.

7. How we can help you

We support you throughout the entire PMCF lifecycle: from deriving precise PMCF questions from CER and PMS, through study design, calculation and setup, to monitoring, biostatics and evaluation. We create PMCF plans and reports and help you with seamless integration with CER/PSUR/Risk File. 

Want to know more? Contact us for a free initial consultation!

You can get a free initial consultation here: free initial consultation